Literature DB >> 24978034

Co-inhibitory pathways and their importance in immune regulation.

Naoka Murakami1, Leonardo V Riella.   

Abstract

Immune regulation is critical for the maintenance of peripheral self-tolerance and for down-regulation of immune responses. Understanding its mechanisms may permit the development of novel targets for the promotion of tolerance in transplantation. Co-inhibitory molecules play a major role in modulating T-cell receptor signaling upon antigen encounter. Their unique patterns of expression, structure, and binding partners account for their diverse function and non-redundancy. Moreover, these inhibitory signals have active roles in both effector and regulatory immune cells in multiple sites, including the target tissue. Herein, we review the recent advances in our understanding of co-inhibitory signaling and its potential clinical applications, focusing mainly on the two best-characterized receptors CTLA4 and PD-1. Recent observations in cancer clinical trials using blocking antibodies against PD-1 or CTLA4, or both, showed a high incidence of autoimmune-related side effects, confirming the important role of these pathways in human immune homeostasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978034     DOI: 10.1097/TP.0000000000000169

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  31 in total

Review 1.  Targeting memory T cells in type 1 diabetes.

Authors:  Mario R Ehlers; Mark R Rigby
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 2.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

3.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

Review 4.  Renal complications of immune checkpoint blockade.

Authors:  Naoka Murakami; Shveta Motwani; Leonardo V Riella
Journal:  Curr Probl Cancer       Date:  2016-12-19       Impact factor: 3.187

5.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Blood Adv       Date:  2020-11-24

6.  Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.

Authors:  Hengcheng Zhang; Zijie Wang; Jiayi Zhang; Zeping Gui; Zhijian Han; Jun Tao; Hao Chen; Li Sun; Shuang Fei; Haiwei Yang; Ruoyun Tan; Anil Chandraker; Min Gu
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 7.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Authors:  Mark R Rigby; Kristina M Harris; Ashley Pinckney; Linda A DiMeglio; Marc S Rendell; Eric I Felner; Jean M Dostou; Stephen E Gitelman; Kurt J Griffin; Eva Tsalikian; Peter A Gottlieb; Carla J Greenbaum; Nicole A Sherry; Wayne V Moore; Roshanak Monzavi; Steven M Willi; Philip Raskin; Lynette Keyes-Elstein; S Alice Long; Sai Kanaparthi; Noha Lim; Deborah Phippard; Carol L Soppe; Margret L Fitzgibbon; James McNamara; Gerald T Nepom; Mario R Ehlers
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

Review 9.  Inhibitory receptors as targets for cancer immunotherapy.

Authors:  Meghan E Turnis; Lawrence P Andrews; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2015-07       Impact factor: 5.532

Review 10.  Immune interventions to preserve β cell function in type 1 diabetes.

Authors:  Mario R Ehlers
Journal:  J Investig Med       Date:  2016-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.